Last reviewed · How we verify
LBR-101 High Dose
At a glance
| Generic name | LBR-101 High Dose |
|---|---|
| Also known as | Fremanezumab |
| Sponsor | Teva Branded Pharmaceutical Products R&D, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine (PHASE2)
- Assessment of LBR-101 In Chronic Migraine (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LBR-101 High Dose CI brief — competitive landscape report
- LBR-101 High Dose updates RSS · CI watch RSS
- Teva Branded Pharmaceutical Products R&D, Inc. portfolio CI